Clinical ResearchRelapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma
Under a Creative Commons license
open archive
Keywords
Allogeneic stem cell transplantation
Dose-reduced conditioning
Nonmyeloablative transplantation
Graft-versus-host disease
Autologous stem cell transplantation
Multiple myeloma
Cited by (0)
Copyright © 2004 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.